Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease

Open access

Abstract

Diabetic kidney disease is the most frequent cause of kidney failure, accounting for half of all cases worldwide. Moreover, deaths from diabetic kidney disease increased 106% between 1990 and 2013, with most attributed to cardiovascular disease. Recommended screening and monitoring for diabetic kidney disease are conducted in less than half of patients with diabetes. Standard-of-care treatment with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker is correspondingly low. Sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and a nonsteroidal mineralocorticoid antagonist are highly effective therapies to reduce kidney and cardiovascular risks in diabetic kidney disease. However, <20% of eligible patients are receiving these agents. Critical barriers are high out-of-pocket drug costs and low reimbursement rates. Data demonstrating clinical and cost-effectiveness of diabetic kidney disease care are needed to garner payer and health care system support. The pharmaceutical industry should collaborate on value-based care by increasing access through affordable drug prices. Additionally, multidisciplinary models and communication technologies tailored to individual health care systems are needed to support optimal diabetic kidney disease care. Community outreach efforts are also central to make care accessible and equitable. Finally, it is imperative that patient preferences and priorities shape implementation strategies. Access to care and implementation of breakthrough therapies for diabetic kidney disease can save millions of lives by preventing kidney failure, cardiovascular events, and premature death. Coalitions composed of patients, families, community groups, health care professionals, health care systems, federal agencies, and payers are essential to develop collaborative models that successfully address this major public health challenge.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2215/cjn.02980322

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

See all 88

Metadata

Authors
Tuttle, K. R., Wong, L., St. Peter, W., Roberts, G., Rangaswami, J., Mottl, A., Kliger, A. S., Harris, R. C., Gee, P. O., Fowler, K., Cherney, D., Brosius, F. C., Argyropoulos, C., & Quaggin, S. E.
Affiliations
  • Northwestern University (US)
  • Department of Pharmaceutical Care and Health Systems, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota
Corresponding author
Tuttle, Katherine R.
Venue
Clinical Journal of the American Society of Nephrology
Published
2022-07
Volume
17
Issue
7
Pages
1092-1103
ISSN
  • 1555-9041 (ISSN-L)
  • 1555-905X
OpenAlex
W4281623679
Cited by
87
References
46
Citations by year
2026: 14 · 2025: 17 · 2024: 38 · 2023: 12 · 2022: 6
FWCI
11.74
Type
journal article
Language
en
Open access
Locations
  • Clinical Journal of the American Society of Nephrology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
diabetic nephropathy, implementation barriers, breakthrough therapies, SGLT2 inhibitors, GLP-1 receptor agonists, mineralocorticoid receptor antagonists, ACE inhibitors, angiotensin receptor blockers, drug costs, reimbursement, value-based care, cost-effectiveness, health care access, community outreach, patient preferences, multidisciplinary care model, cardiovascular risk, kidney failure prevention
MeSH terms
Mineralocorticoid Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Humans, Renal Insufficiency, Angiotensin Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease. https://app.cochat.ai/papers/10.2215/cjn.02980322
The paper
Tuttle, K. R., Wong, L., St. Peter, W., Roberts, G., Rangaswami, J., Mottl, A., Kliger, A. S., Harris, R. C., Gee, P. O., Fowler, K., Cherney, D., Brosius, F. C., Argyropoulos, C., & Quaggin, S. E. (2022). Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.02980322

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.